Search PubMed⌕ Search

Biomedical subjects

Scott Smith

Publications and source records attributed to Scott Smith.

20 records · Page 2Linked to original sources

S-adenosyl-L-methionine (SAMe) for the treatment of acetaminophen toxicity in a dog.

An 8-month-old, spayed female Shetland sheepdog presented 48 hours after ingesting acetaminophen (1 gm/kg body weight). On presentation, the dog was laterally recumbent and hypovolemic. The dog had brown mucous membranes, severe Heinz-body hemolytic anemia, bleeding tendencies, and a red blood cell (RBC) glutathione (GSH) concentration that was 10% of reference values, despite a regenerative erythroid response. Treatment with s-adenosyl-l-methionine (SAMe) as a GSH donor successfully rescued this dog, despite the animal's late presentation after drug ingestion. A loading dose (40 mg/kg body weight) of a stable SAMe salt per os was followed by a maintenance dose (20 mg/kg body weight) sid for 7 days. Additional therapeutic interventions included an intravenous (i.v.) infusion of one unit of packed RBCs (on admission), i.v. fluid support (3 days), and famotidine (7 days) to reduce gastric acidity. Sequential assessment of RBC GSH concentrations and RBC morphology documented response to antidote administration within 72 hours. This case suggests that SAMe may provide a therapeutic option for treatment of acetaminophen toxicosis in dogs capable of retaining an orally administered antidote and maintaining adequate hepatic function for metabolism of SAMe to its thiol substrates.

Acetaminophen↗

Using host response modifiers in the treatment of periodontal disease. "The clinicians' view". [Interview].

While considerable advances have been made in the understanding of the tissue-destructive mechanisms involved in etiology of periodontitis, the adoption and application of this knowledge has not been generally incorporated into the daily management of patients with chronic periodontitis. A number of adjunctive pharmacotherapeutic agents have been investigated in clinical trials and several agents are used in everyday practice as adjuncts to mechanical nonsurgical periodontal therapy. The only systemic, host modulatory agent approved for the adjunctive use with nonsurgical periodontal procedures, however, is Periostat (20mg doxycycline hyclate, twice daily). In order to further understand the impact of adjunctive host modulatory therapy on patient management and its role in clinical practice, Montage Media interviewed dental professionals across the US. Each of the participants has direct experience with the use of Periostat in their clinical practice. The expectation is that, with the "real life" clinical experience reported by clinicians "in their own words" coupled with the extensive literature describing the results of controlled clinical trials of Periostat, it will be possible to hasten the adoption of evidence-based science into clinical practice.

Dentist-Patient Relations↗